Hostname: page-component-586b7cd67f-t7czq Total loading time: 0 Render date: 2024-11-24T17:58:37.281Z Has data issue: false hasContentIssue false
  • English
  • Français

Vascular endothelial growth factor and its soluble receptor in infants with congenital cardiac disease

Published online by Cambridge University Press:  17 May 2010

Anja Pohl-Schickinger ,
Petra Koehne ,
Thomas Schmitz ,
Katharina R. L. Schmitt ,
Michael Hübler ,
Matthias Redlin ,
Felix Berger  and
Brigitte Stiller
Anja Pohl-Schickinger*
Affiliation:
Department of Neonatology, Charité University Medicine Berlin, Campus Virchow Klinikum, Berlin, Germany
Petra Koehne
Affiliation:
Department of Neonatology, Charité University Medicine Berlin, Campus Virchow Klinikum, Berlin, Germany
Thomas Schmitz
Affiliation:
Department of Neonatology, Charité University Medicine Berlin, Campus Virchow Klinikum, Berlin, Germany
Katharina R. L. Schmitt
Affiliation:
Department of Congenital Heart Disease, Campus Virchow Klinikum, Berlin, Germany
Michael Hübler
Affiliation:
Department of Cardiothoracic and Vascular Surgery, Campus Virchow Klinikum, Berlin, Germany
Matthias Redlin
Affiliation:
Department of Anesthesia, Deutsches Herzzentrum Berlin, Campus Virchow Klinikum, Berlin, Germany
Felix Berger
Affiliation:
Department of Congenital Heart Disease, Deutsches Herzzentrum Berlin and Charité University Medicine Berlin, Campus Virchow Klinikum, Berlin, Germany
Brigitte Stiller
Affiliation:
Department of Congenital Heart Disease, Campus Virchow Klinikum, Berlin, Germany Department of Congenital Heart Disease, Childrens University Hospital, Freiburg, Germany
*
Correspondence to: Dr A. Pohl-Schickinger, Department of Neonatology, Charité University Medicine Berlin, Campus Virchow Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany. Tel: 0049 30 450 566 122; Fax: 0049 30 450 566 922; E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Patients with cyanotic congenital cardiac disease often develop major aortopulmonary collaterals. Vascular endothelial growth factor is a key promoter of angiogenesis. Its soluble receptor-1 acts as a potent antagonist. We studied 30 infants with cyanotic congenital cardiac disease and 27 infants with acyanotic congenital cardiac disease. Central venous plasma vascular endothelial growth factor and soluble vascular endothelial growth factor receptor-1 levels were measured before, and 24 and 96 hours after surgery. There was no difference between plasma vascular endothelial growth factor levels in infants with cyanotic and those with acyanotic congenital cardiac disease. In cyanotic infants, the soluble vascular endothelial growth factor receptor-1 levels tended to be higher than in the acyanotic infants. In conclusion, there is no significant difference in the plasma levels of vascular endothelial growth factor and its soluble receptor-1 between infants with cyanotic and those with acyanotic congenital cardiac disease.

Keywords

Angiogenesiscardiopulmonary bypassmajor aortopulmonary collaterals
Type
Original Articles
Information
Cardiology in the Young , Volume 20 , Issue 5 , October 2010 , pp. 505 - 508
Copyright
Copyright © Cambridge University Press 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Ootaki, Y, Yamaguchi, M, Yoshimura, N, Oka, S, Yoshida, M, Hasegawa, T. Vascular endothelial growth factor in children with congenital heart disease. Ann Thorac Surg 2003; 75: 1523–1526.CrossRefGoogle ScholarPubMed
2. Suda, K, Matsumura, M, Miyanish, S, Uehara, K, Sugita, T, Matsumoto, M. Increased vascular endothelial growth factor in patients with cyanotic congenital heart diseases may not be normalized after a Fontan type operation. Ann Thorac Surg 2004; 78: 942–946; discussion 946–947.CrossRefGoogle Scholar
3. Klagsbrun, M, D’Amore, PA. Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev 1996; 7: 259–270.CrossRefGoogle ScholarPubMed
4. Kendall, RL, Thomas, KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 1993; 90: 10705–10709.CrossRefGoogle ScholarPubMed
5. Shibuya, M. Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis. Angiogenesis 2006; 9: 225–230; discussion 231.CrossRefGoogle ScholarPubMed
6. Starnes, SL, Duncan, BW, Kneebone, JM, et al. Vascular endothelial growth factor and basic fibroblast growth factor in children with cyanotic congenital heart disease. J Thorac Cardiovasc Surg 2000; 119: 534–539.CrossRefGoogle ScholarPubMed
7. Himeno, W, Akagi, T, Furui, J, et al. Increased angiogenic growth factor in cyanotic congenital heart disease. Pediatr Cardiol 2003; 24: 127–132.CrossRefGoogle ScholarPubMed
8. Webb, NJ, Bottomley, MJ, Watson, CJ, Brenchley, PE. Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease. Clin Sci (Lond) 1998; 94: 395–404.CrossRefGoogle ScholarPubMed
9. Hormbrey, E, Gillespie, P, Turner, K, et al. A critical review of vascular endothelial growth factor (VEGF) analysis in peripheral blood: is the current literature meaningful? Clin Exp Metastasis 2002; 19: 651–663.CrossRefGoogle ScholarPubMed
10. Arena, E, Ferrero, S. Pitfalls in the measurement of serum VEGF in children with congenital heart disease. Ann Thorac Surg 2004; 78: 1884–1885.CrossRefGoogle ScholarPubMed
11. Hamada, H, Ebata, R, Higashi, K, et al. Serum vascular endothelial growth factor in cyanotic congenital heart disease functionally contributes to endothelial cell kinetics in vitro. Int J Cardiol 2007; 120: 66–71.CrossRefGoogle ScholarPubMed